Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
2.150
+0.650 (43.33%)
At close: Apr 15, 2025, 4:00 PM
2.190
+0.040 (1.86%)
After-hours: Apr 15, 2025, 6:37 PM EDT
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -78.48% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 21.8, with a low estimate of 16 and a high estimate of 30. The average target predicts an increase of 913.95% from the current stock price of 2.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +783.72% | Mar 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 26, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $17 | Buy | Reiterates | $17 | +690.70% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $19 | Strong Buy | Maintains | $22 → $19 | +783.72% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 31, 2025 |
Financial Forecast
Revenue This Year
n/a
from 279.05M
Revenue Next Year
n/a
EPS This Year
-2.87
from -2.38
EPS Next Year
-2.88
from -2.87
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2M | 60.2M | 179.8M | ||
| Avg | 350,431 | 10.1M | 54.4M | ||
| Low | n/a | n/a | 2.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -98.8% | 17,091.7% | 1,676.8% | ||
| Avg | -99.9% | 2,787.9% | 437.4% | ||
| Low | - | - | -74.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.19 | -1.93 | -1.55 | ||
| Avg | -2.87 | -2.88 | -2.76 | ||
| Low | -3.87 | -3.33 | -4.75 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.